Washington (ANI): Lynne Spears' mother has denied reports she sent pregnant 17-year-old Bristol Palin a baby gift software package on behalf of her teenage daughter. Recently, rumours were abuzz that Jamie-Lynn, a teenaged mum herself, had mail-clad the daughter of frailty presidential candidate Sarah Palin 60 pink dollars belch cloths from L.A. baby boutique Petit Tresor, reports Us magazine.
A computer storage rep even told ABC News that Spears included a card with the package: 'Dear Bristol, Hang in there! XXOO, Jamie Lynn Spears.' But Lynne Spears has denied the claims. A Spears rep told E! News: "I just got off the phone with Lynne. I can tell you that she hasn't sent her any gifts, but that she does support Sarah and, of course, lav empathize with their situation."
More info
Monday, 8 September 2008
Friday, 29 August 2008
Mp3 music: Am I Blood
 Artist: Am I Blood: mp3 download Genre(s): Metal: Thrash Am I Blood's discography:  Agitation Year: 1998 Tracks: 11 Formed in 1992 under the original sobriquet St. Mucus, Am I Blood comply in the Finland tradition of 90's aggressive metal with more an wrath tincture, rather than cheesy pop metal that this genre was feel for antecedently. With the sacking of their number one 2 albums "Natural Mutation" and "Am I Blood" -which were distributed in limited quantities end-to-end EuropeJanne Kermine (vocals/ guitar), Pekka Kulmala (guitar) Toni Gronros (bass), and Sauli Suomalainen (drums) finally hit that Western market crossways the Atlantic with the dismission of "Fermentation" in 1998; thanks to the avail of Nuclear Blast Records. |
FDA Requires Additional Information On DORIBAX For Treatment Of Hospital-Acquired Pneumonia
Tuesday, 19 August 2008
Global Phase 3 Study Of IMC-1121B In Metastatic Breast Cancer Commences
�ImClone Systems Incorporated (NASDAQ: IMCL), a global loss leader in the development and commercialization of novel antibodies to treat cancer, today announced that the first patient has been hardened in a global Phase 3 clinical trial of IMC-1121B, its anti-vascular endothelial growth factor receptor-2 (VEGFR-2) IgG1 monoclonal antibody antibody, in women with metastatic white meat cancer.
"Since the growth of breast cancer is dependent on VEGFR-2 activation, IMC-1121B presents a unique opportunity to optimize this therapeutic approaching as IMC-1121B uniquely binds to the VEGFR-2 sensory receptor itself, thereby blocking many VEGF ligands from activating it," aforementioned Eric K. Rowinsky, M.D., Executive Vice President and Chief Medical Officer of ImClone. "Unlike bevacizumab that targets only when a single ligand, and unlike small molecule drugs that target many unrelated receptors, IMC-1121B specifically targets only VEGFR-2. This clinical trial will help us understand whether this access produces greater activity with fewer position effects."
In April 2008, ImClone proclaimed the establishment of an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for this test. The SPA is a written agreement between the trial's sponsor and the FDA regarding the design and size of the Phase 3 trial to be secondhand in generating the primary clinical data necessary to support approval of an efficacy claim in conjunction with the submission of a new drug lotion (NDA) or biologics licensing application (BLA).
Pursuant to the SPA, this Phase 3 trial is a randomized, double blind, placebo-controlled test of IMC-1121B plus docetaxel in women with unresectable locally-recurrent or metastatic titty cancer world Health Organization have non received prior chemotherapy in the locally-recurrent or metastatic setting. The trial, which is being conducted under the auspices of the Cancer International Research Group, doing occupation as Translational Research in Oncology (TRIO), is expected to recruit approximately 1,100 patients who testament be randomised (2:1) to receive either IMC-1121B plus docetaxel or placebo plus docetaxel. The elemental endpoint of the trial is progression-free survival. The trial testament be conducted at more than 200 sites throughout the public.
"This visitation of IMC-1121B highlights the efforts of TRIO to bring bright new therapies to women with bosom cancer, which remains the most oftentimes diagnosed cancer among women today," aforementioned John Mackey, M.D., FRCPC, Professor of Oncology at the University of Alberta, and Principal Investigator of the study. "Our efforts also demonstrate TRIO's commitment to transforming our agreement of crab biology into clinical trials by testing compounds, like IMC-1121B, crossways the spectrum of human cancer."
IMC-1121B is a fully human IgG1 monoclonal antibody intentional to tie to the extracellular domain of VEGFR-2 found on tumor vasculature, thereby inhibiting certain ligands known as vascular endothelial growth factors from bandaging to and activating the receptor. This action blocks a sign pathway key to new blood vessel formation in growing tumors, which has been shown to starve tumors of their nutrient supply and result in significant tumour growth inhibition in presymptomatic models. In 2007, ImClone completed enrollment into deuce Phase 1 studies of IMC-1121B, which demonstrated favorable safety and pharmacokinetic profiles, as well as nonsubjective antitumor activity as a single agent in several patients with refractory solid cancers when administered either weekly or every 2 or trey weeks. In addition to this Phase 3 survey of IMC-1121B in women with breast cancer, disease-directed studies of IMC-1121B in patients with advanced melanoma, renal and liver cancers have begun to enter patients, and additional Phase 2 and 3 evaluations are in various stages of development.
About TRIO
TRIO, which was created as an international research network in oncology in 1997, is an academic global network of investigators capable of rapid accrual to clinical trials. TRIO arose kayoed of the need to address the increasing figure of new anticancer drugs and targeted therapies in development. TRIO has selected dedicated investigators from all around the world to participate in pivotal trials of new cancer agents in tit cancer and many other disease settings. TRIO has been highly successful in maintaining a strong and enthusiastic network by offer innovative and exciting science, and more than recently, translational research. TRIO consists of an operations infrastructure that uses comprehensive pharmaceutical industry standards. By combining these two strategies, that of increasing patient access through global police detective sites and that of applying efficient, well-established clinical trial operation systems, TRIO has since become recognised for its high quality data and rapid accumulation rates. TRIO has besides been highly successful at captivating the interests of patients and investigators throughout the world, in part, due to the internalization of high quality and exciting science into its clinical evaluations. TRIO was incorporated as a Canadian not for profit entity in 1999.
About ImClone Systems
ImClone Systems Incorporated is a fully integrated global biopharmaceutical company committed to forward-moving oncology attention by development and commercializing a portfolio of targeted biologic treatments designed to address the medical of necessity of patients with a variety of cancers. The Company's research and evolution programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research trading operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey. For more than information around ImClone Systems, please visit the Company's web site at hypertext transfer protocol://www.imclone.com.
Certain matters discussed in this news release may found forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such advanced statements are based upon reasonable assumptions it bathroom give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could movement actual results to differ materially from those currently expected. Many of these factors are beyond the company's ability to control or auspicate. Important factors that may cause literal results to differ materially and could impact the company and the statements contained in this news release tin be launch in the company's filings with the Securities and Exchange Commission, particularly those factors identified as "peril factors" in the Company's most late annual report of Form 10-K and in its quarterly reports on Form 10-Q and current reports on Form 8-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement whatever forward-looking statements whether as a solvent of new information, future events or otherwise.
ImClone Systems
More info
"Since the growth of breast cancer is dependent on VEGFR-2 activation, IMC-1121B presents a unique opportunity to optimize this therapeutic approaching as IMC-1121B uniquely binds to the VEGFR-2 sensory receptor itself, thereby blocking many VEGF ligands from activating it," aforementioned Eric K. Rowinsky, M.D., Executive Vice President and Chief Medical Officer of ImClone. "Unlike bevacizumab that targets only when a single ligand, and unlike small molecule drugs that target many unrelated receptors, IMC-1121B specifically targets only VEGFR-2. This clinical trial will help us understand whether this access produces greater activity with fewer position effects."
In April 2008, ImClone proclaimed the establishment of an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for this test. The SPA is a written agreement between the trial's sponsor and the FDA regarding the design and size of the Phase 3 trial to be secondhand in generating the primary clinical data necessary to support approval of an efficacy claim in conjunction with the submission of a new drug lotion (NDA) or biologics licensing application (BLA).
Pursuant to the SPA, this Phase 3 trial is a randomized, double blind, placebo-controlled test of IMC-1121B plus docetaxel in women with unresectable locally-recurrent or metastatic titty cancer world Health Organization have non received prior chemotherapy in the locally-recurrent or metastatic setting. The trial, which is being conducted under the auspices of the Cancer International Research Group, doing occupation as Translational Research in Oncology (TRIO), is expected to recruit approximately 1,100 patients who testament be randomised (2:1) to receive either IMC-1121B plus docetaxel or placebo plus docetaxel. The elemental endpoint of the trial is progression-free survival. The trial testament be conducted at more than 200 sites throughout the public.
"This visitation of IMC-1121B highlights the efforts of TRIO to bring bright new therapies to women with bosom cancer, which remains the most oftentimes diagnosed cancer among women today," aforementioned John Mackey, M.D., FRCPC, Professor of Oncology at the University of Alberta, and Principal Investigator of the study. "Our efforts also demonstrate TRIO's commitment to transforming our agreement of crab biology into clinical trials by testing compounds, like IMC-1121B, crossways the spectrum of human cancer."
IMC-1121B is a fully human IgG1 monoclonal antibody intentional to tie to the extracellular domain of VEGFR-2 found on tumor vasculature, thereby inhibiting certain ligands known as vascular endothelial growth factors from bandaging to and activating the receptor. This action blocks a sign pathway key to new blood vessel formation in growing tumors, which has been shown to starve tumors of their nutrient supply and result in significant tumour growth inhibition in presymptomatic models. In 2007, ImClone completed enrollment into deuce Phase 1 studies of IMC-1121B, which demonstrated favorable safety and pharmacokinetic profiles, as well as nonsubjective antitumor activity as a single agent in several patients with refractory solid cancers when administered either weekly or every 2 or trey weeks. In addition to this Phase 3 survey of IMC-1121B in women with breast cancer, disease-directed studies of IMC-1121B in patients with advanced melanoma, renal and liver cancers have begun to enter patients, and additional Phase 2 and 3 evaluations are in various stages of development.
About TRIO
TRIO, which was created as an international research network in oncology in 1997, is an academic global network of investigators capable of rapid accrual to clinical trials. TRIO arose kayoed of the need to address the increasing figure of new anticancer drugs and targeted therapies in development. TRIO has selected dedicated investigators from all around the world to participate in pivotal trials of new cancer agents in tit cancer and many other disease settings. TRIO has been highly successful in maintaining a strong and enthusiastic network by offer innovative and exciting science, and more than recently, translational research. TRIO consists of an operations infrastructure that uses comprehensive pharmaceutical industry standards. By combining these two strategies, that of increasing patient access through global police detective sites and that of applying efficient, well-established clinical trial operation systems, TRIO has since become recognised for its high quality data and rapid accumulation rates. TRIO has besides been highly successful at captivating the interests of patients and investigators throughout the world, in part, due to the internalization of high quality and exciting science into its clinical evaluations. TRIO was incorporated as a Canadian not for profit entity in 1999.
About ImClone Systems
ImClone Systems Incorporated is a fully integrated global biopharmaceutical company committed to forward-moving oncology attention by development and commercializing a portfolio of targeted biologic treatments designed to address the medical of necessity of patients with a variety of cancers. The Company's research and evolution programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research trading operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey. For more than information around ImClone Systems, please visit the Company's web site at hypertext transfer protocol://www.imclone.com.
Certain matters discussed in this news release may found forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such advanced statements are based upon reasonable assumptions it bathroom give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could movement actual results to differ materially from those currently expected. Many of these factors are beyond the company's ability to control or auspicate. Important factors that may cause literal results to differ materially and could impact the company and the statements contained in this news release tin be launch in the company's filings with the Securities and Exchange Commission, particularly those factors identified as "peril factors" in the Company's most late annual report of Form 10-K and in its quarterly reports on Form 10-Q and current reports on Form 8-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement whatever forward-looking statements whether as a solvent of new information, future events or otherwise.
ImClone Systems
More info
Saturday, 9 August 2008
Blackfoot
Artist: Blackfoot
Genre(s):
Rock
Other
Rock: Hard-Rock
Discography:
Rattlesnake Rock 'N' Roll: The Best Of Blackfoot
Year: 1994
Tracks: 13
Vertical Smiles
Year: 1984
Tracks: 9
Siogo
Year: 1983
Tracks: 10
Highway Song Live
Year: 1982
Tracks: 11
Marauder
Year: 1981
Tracks: 9
Tomcattin'
Year: 1980
Tracks: 10
Strikes
Year: 1979
Tracks: 10
Flyin' High
Year: 1976
Tracks: 10
Blackfoot were coevals of Lynyrd Skynyrd, and tried for age to draw in it as a Southern rock banding, although they finally succeeded as a concentrated rock kit, in the trend of AC/DC and the Scorpions. They racked up a fall album (Strikes) and a pair of successful singles ("Prepare, Train," "Highway Song") in the late 1970s and early 1980s, earlier they became lost in the post-MTV era of visually oriented bands.
The group started out as a quadruple: singer/guitarist Rickey Medlocke, the grandson of blue grass musician Shorty Medlocke, world Health Organization wrote "Train, Train"; drummer/singer Jakson Spires, bassist/singer Greg T. Walker, and lead guitar player Charlie Hargrett. They were signed to Island Records in 1975, obviously as that label's resident Southern rockers, only stirred to Epic Records the following year. Neither relationship was successful, only in 1979, afterward moving to Atco, their first album for the new label, Strikes, hit a reactive chord -- the grouping spent the following few old age on Atco, racking up telling gross sales with the follow-ups Tomcattin' and Piranha.
In the mid-'80s, the group added ex-Uriah Heep keyboardman Ken Hensley in order to impart a new side to their sound. The group's fortunes declined amid the advent of MTV and the growth in grandness of sway video promotional clips, as well as the influence of sounds from Europe and Australia, and they never recovered, scorn efforts to accommodate their sound and picture. Hensley was replaced dear the ending of their history, just Blackfoot (world Health Organization took their call from the Native American tribe, parting of Medlocke's inheritance) had humiliated up by 1984, earlier the new lineup recorded. Medlocke revived the call in 1990 with a new patronage group.
Emmis Interactive Unveils Suite of Custom Products, Tools and Games
Tuesday, 1 July 2008
Tuesday, 24 June 2008
Unity Dub
Artist: Unity Dub
Genre(s):
Reggae
Discography:
Unity Dub - Voyage In To Paradise
Year: 2002
Tracks: 1
Monday, 16 June 2008
Clay Walker
Artist: Clay Walker
Genre(s):
Country
Pop
Discography:
Fall
Year: 2007
Tracks: 12
A Few Questions
Year: 2003
Tracks: 13
Live Laugh Love
Year: 2000
Tracks: 11
Rumor Has It
Year: 1997
Tracks: 10
If I Could Make a Living
Year: 1995
Tracks: 11
Hypnotize the Moon
Year: 1995
Tracks: 11
Clay Walker
Year: 1993
Tracks: 11
With his first 2 singles reach number unrivaled upon their release, Clay Walker directly effected himself as a commercial success. Unlike most of his new country coevals of the mid-'90s, he was able to support that success over a couple of age, wrenching up no less than 5 numeral one singles in the first three age of his calling.
Alice Walker (born August 19, 1969) was born and embossed on a farm in Beaumont, TX, the hometown of George Jones. He hide in love with country music at an early age, when his padre gave him a guitar when he was exclusively nine age older. After he calibrated from high school, Walker pursued a musical career full-time, playing concerts across the South, the Midwest, and Canada. For over 3 eld, he toured and went to school, taking courses about the music patronage. During this time, he acted as his have director. Eventually, he became the house isaac M. Singer at the Neon Armadillo measure in Beaumont. While playacting at the society, manufacturer James Stroud heard Walker and offered to work with the isaac M. Singer. Stroud helped Walker procure a contract with Giant Records, and the pair began working on the vocalist's debut album.
"What's It to You" became a numeral unitary bump off upon its release in August of 1993, with "Live Until I Die" following it into the pole side subsequently that same twelvemonth. Both singles were featured on his debut album, Henry Clay Walker, which was released in the fall of 1993. "Where Do I Fit in the Picture," the tierce single from the album, became a number 11 hit in former 1994. "Edward Douglas White Jr. Palace" was a fizzle, weakness to crack the Top 40, but "Dreaming with My Eyes Open" became his tierce number one tally in the summertime of 1994, portion build his debut record a pt album. If I Could Make a Living was not quite a as successful as his debut, yet it smooth yielded the number one title runway. Mesmerise the Moon, Walker's tierce record album, appeared in the fall of 1995, preceded by the number 2 undivided "WHO Needs You Baby." He followed with Self Portrait in 1996 and Hearsay Has It in 1997. A Superlative Hits collection appeared in 1998 and a new album, Hot, Laugh, Love, was released in 1999. Enjoin No More followed iI age subsequently, with A Few Questions arriving in 2003 and Fall in 2007.
Subscribe to:
Posts (Atom)